Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 7/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982265 | 0.92 | PARP1 (0.36) | PARP1ALDH1A1LMNAMAPTTSHR | |
| SCHEMBL3985369 | 0.91 | LMNA (0.36) | PARP1P2RX7ALDH1A1LMNAMAPT | |
| SCHEMBL3983968 | 0.90 | PIK3CD (0.39) | PARP1ALDH1A1MAPTTSHR | |
| SCHEMBL3981550 | 0.89 | PIK3CD (0.33) | PARP1KCNH2ALDH1A1LMNAMAPT | |
| SCHEMBL3986939 | 0.89 | PARP1 (0.33) | PARP1PARP2P2RX7 | |
| SCHEMBL3987232 | 0.88 | PTGER4 (0.35) | P2RX7 | |
| SCHEMBL1387060 | 0.88 | ALDH1A1 (0.36) | PARP1PARP2KCNH2ALDH1A1LMNA | |
| SCHEMBL3984446 | 0.87 | PTGER4 (0.37) | P2RX7 | |
| SCHEMBL3988126 | 0.87 | PTGER4 (0.34) | P2RX7 | |
| SCHEMBL3982488 | 0.86 | PTGER4 (0.33) | P2RX7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | claimed |
| EP-1756114-B1 | HIV INTEGRASE INHIBITORS | MERCK SHARP & DOHME (US) | 2014-11-19 | — | — | EP | disclosed |
| US-7538112-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080287394-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287394-A1 | Hiv Integrase Inhibitors | DHPS, DPYD, TYMP | PARP1 196/4885PARP2 708/4885P2RX7 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.